53. Sjogren syndrome Clinical trials / Disease details

Clinical trials : 305 / Drugs : 325 - (DrugBank : 104) / Drug target genes : 58 - Drug target pathways : 188

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR2200057578	2022-03-01	2022-03-15	Tofacitinib treatment in patients with primary Sjogren syndrome: a prospective pilot trial	Tofacitinib treatment in patients with primary Sjogren syndrome: a prospective pilot trial	Sjogren Syndrome	Control group:Same dose of hydroxychloroquine sulfate as before;Intervention group:Tofacitinib 5mg bid po+the same dose of hydroxychloroquine sulfate as before;	Ningbo Medical Center Lihuili Hospital	NULL	Pending	15	70	Both	Control group:60;Intervention group:60;	Phase 4	China
2	NCT05087589 (ClinicalTrials.gov)	November 20, 2021	8/10/2021	Efficacy, Safety and Immunological Evaluation of Tofacitinib in the Treatment of Primary Sjogren's Syndrome	Efficacy, Safety and Immunological Evaluation of Tofacitinib in the Treatment of Primary Sjögren's Syndrome:a Prospective Observational Study	Primary Sjögren's Syndrome	Drug: Tofacitinib	Peking University People's Hospital	NULL	Recruiting	18 Years	N/A	All	10	Phase 2	China
3	NCT04496960 (ClinicalTrials.gov)	May 18, 2021	2/8/2020	Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren's Syndrome	Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sj(SqrRoot)(Delta)Gren's Syndrome; a Phase Ib-IIa Placebo-controlled Clinical Trial and Associated Mechanistic Studies	Sjogren's Syndrome	Drug: tofacitinib;Other: Placebo	National Institute of Dental and Craniofacial Research (NIDCR)	NULL	Recruiting	18 Years	75 Years	All	30	Phase 1/Phase 2	United States